Aug 18, 2020 / 08:00AM GMT
Richard Godfrey - BerGenBio ASA - CEO
Hello. Good morning. Welcome to BerGenBio's quarter 2 half year report highlight 2020. My name is Richard Godfrey, I'm the CEO of BerGenBio. And I'm joined by Rune Skeie, our CFO; Hani Gabra, our Chief Medical Officer; and James Lorens, our Chief Scientific Officer.
I'd like to give a special welcome to our new shareholders. We have more than 10,000 shareholders in the company now, and I'd also like to extend a special welcome to new international shareholders that have recently joined our register.
Next slide, please. We are, of course, a public company, and I should draw your attention to these forward-looking statements and ask that you pay attention to the details.
Next slide, please, Slide 3. By way of a corporate overview and introduction, BerGenBio is a world leader in understanding the role and function of AXL biology. AXL is a tyrosine kinase that drives aggressive disease including immune-evasion, therapy-resistant and metastatic cancer, fibrosis and also viral infections. BerGenBio has a number of inhibitors of AXL in clinical
Q2 2020 Bergenbio ASA Earnings Call Transcript
Mar 02, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers